Steven Cohen Nurix Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

$44.6 Billion
Q2 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 3,703,594 shares of NRIX stock, worth $37.1 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

3,703,594

Previous 218,453 1595.37%

Holding current value

$37.1 Million

Previous $2.6 Million 1525.55%

% of portfolio

0.09%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$8.81 - $12.79 $30.7 Million - $44.6 Million	3,485,141 Added 1595.37%	3,703,594 $42.2 Million
Q1 2025 May 15, 2025	SELL	$11.88 - $20.15 $7.78 Million - $13.2 Million	-654,506 Reduced 74.98%	218,453 $2.6 Million
Q4 2024 Feb 14, 2025	BUY	$18.64 - $28.14 $16.3 Million - $24.6 Million	872,959 New	872,959 $16.4 Million
Q1 2024 May 15, 2024	BUY	$7.77 - $15.66 $73,815 - $148,770	9,500 New	9,500 $139,000
Q3 2023 Nov 14, 2023	BUY	$7.86 - $10.08 $8,701 - $11,158	1,107 Added 15814.29%	1,114 $8,000
Q2 2023 Aug 14, 2023	SELL	$8.7 - $13.28 $83,467 - $127,408	-9,594 Reduced 99.93%	7 $0
Q1 2023 May 15, 2023	BUY	$8.56 - $13.26 $82,184 - $127,309	9,601 New	9,601 $85,000
Q2 2022 Aug 15, 2022	SELL	$7.88 - $14.82 $550,418 - $1.04 Million	-69,850 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$12.94 - $29.65 $863,098 - $1.98 Million	-66,700 Reduced 48.85%	69,850 $979,000
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $3.61 Million - $4.71 Million	136,550 New	136,550 $3.95 Million

Others Institutions Holding NRIX

# of Institutions

174

Shares Held

79.4M

Call Options Held

126K

Put Options Held

11.3K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $472M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account